RICHMOND, British Columbia, Oct. 31, 2006 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) is pleased to announce that it will appear on the broadcast television show Your Cancer Today. The scheduled date is the weekend of November 4th and 5th, 2006.
During the interview, BioCurex discusses the RECAF technology allowing the detection of the majority of cancers with a basic blood test, along with the potential use of RECAF for imaging the location of the cancer and for cancer therapy. The importance of cancer diagnosis using a simple inexpensive blood test is discussed as it pertains to reducing overall medical costs, but an emphasis is also placed upon the individual patient that would benefit by the early stage cancer detection or by monitoring for any recurrence of a treated cancer. BioCurex has the potential to dramatically enhance medical care through early cancer detection of all the major cancers including cancer of the prostate, breast, lung, colon, stomach, ovaries and others.
Your Cancer Today is a television show with a related internet web site. The Show explores cancer diagnosis and treatment and current research breakthroughs with expert commentators. The show is intended to inform and educate viewers. A list of the broadcast coverage areas, show times and broadcasting stations can be found at their web site -- www.YourCancerToday.com. Your Cancer Today(tm) is being produced by an experienced team of television and entertainment industry experts. This team together with writers, researchers and an advisory board of Medical Doctors, seek to enable viewers to gain knowledge and have the power of choice.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(tm) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.